The role of rasagiline in the treatment of Parkinson's disease.
Article Details
- CitationCopy to clipboard
Leegwater-Kim J, Bortan E
The role of rasagiline in the treatment of Parkinson's disease.
Clin Interv Aging. 2010 May 25;5:149-56.
- PubMed ID
- 20517484 [ View in PubMed]
- Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing. In several large, randomized, placebo-controlled trials, rasagiline has demonstrated efficacy as monotherapy in early PD and as adjunctive therapy in advanced PD. In addition, rasagiline has been shown to have neuroprotective effects in in vitro and in vivo studies. The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Rasagiline Amine oxidase [flavin-containing] B Protein Humans YesInhibitorDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Rasagiline Cytochrome P450 1A2 Protein Humans UnknownSubstrateDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareRasagilineFluvoxamine The serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine. RasagilineEnoxacin The serum concentration of Rasagiline can be increased when it is combined with Enoxacin. RasagilineRofecoxib The serum concentration of Rasagiline can be increased when it is combined with Rofecoxib. RasagilineCiprofloxacin The serum concentration of Rasagiline can be increased when it is combined with Ciprofloxacin. RasagilineQuinidine The serum concentration of Rasagiline can be increased when it is combined with Quinidine.